Beta-caryophyllene (often shortened to BCP) gives black pepper and cloves their spicy, woody bite, and it is a major terpene in many cannabis varieties. In 2008, researchers reported in PNAS that it binds to and activates the CB2 cannabinoid receptor, earning it the label “dietary cannabinoid.” That finding is solid, but it is often stretched into treatment claims that the research does not support.

Beta-caryophyllene selectively binds the CB2 receptor and activates it. CB2 is mostly involved in immune signaling; it is not the CB1 receptor responsible for THC’s high. In mice, oral beta-caryophyllene reduced inflammation and some kinds of pain, and those effects disappeared in mice lacking CB2. We found no controlled human trials testing it as part of cannabis.
What the 2008 Discovery Showed
A team led by Jürg Gertsch at ETH Zurich reported that (E)-beta-caryophyllene binds selectively to the CB2 receptor and acts as a functional agonist, meaning it switches the receptor on. In human immune cells it reduced inflammatory signaling. In mice, an oral dose of 5 mg per kg reduced inflammation in a standard test, but not in mice bred without CB2 receptors. That last detail is what makes the finding convincing: the effect depended on the receptor. The authors described it as a “nonpsychoactive” CB2 ligand found in foods and in cannabis.
Pain Studies in Mice
A 2014 follow-up in European Neuropsychopharmacology found that oral beta-caryophyllene reduced inflammatory pain responses in mice in a CB2-dependent way, while it had no effect on acute pain. In a nerve-pain model, longer-term treatment reduced pain sensitivity and spinal inflammation, and the mice did not develop tolerance. These are promising animal results. They have not been confirmed in controlled human trials of cannabis or beta-caryophyllene for pain.
How It Fits the Entourage Debate
Beta-caryophyllene is the terpene that holds up best in receptor studies. A 2020 study that found no cannabinoid-receptor activity for other common terpenes still noted a possible weak interaction of beta-caryophyllene with CB2. A 2019 study using a different method found no CB2 activation from it. So even here the lab picture is not unanimous, and receptor activity in cells does not show that the amount in cannabis changes how a person feels. See our entourage effect review.
CB1 vs. CB2: Why It Won’t Get You High
| Receptor | Where it’s mostly found | Beta-caryophyllene? |
|---|---|---|
| CB1 | Brain and nervous system; drives THC’s intoxicating effects | Not a target; the 2008 study found it binds selectively to CB2 |
| CB2 | Immune cells and peripheral tissues; involved in inflammation | Binds and activates it selectively |
Because it targets CB2 rather than CB1, beta-caryophyllene is not intoxicating. It is used as a flavoring in food, and you eat it whenever you use black pepper.
What This Means for You
- Beta-caryophyllene is one of the more scientifically interesting terpenes, and a peppery, spicy profile is a fair thing to look for on a lab report.
- Be skeptical of products that promise pain or inflammation relief because they contain it. The supporting studies are in mice.
- If you are managing pain, talk with a clinician. Our chronic pain research review covers what human cannabis studies show.
Clear answers
Frequently Asked Questions
Is Beta-Caryophyllene a Cannabinoid?
Chemically it is a terpene, but it acts like a cannabinoid at one receptor. A 2008 PNAS study showed it binds and activates CB2, and the authors called it a dietary cannabinoid.
Does Beta-Caryophyllene Get You High?
No. It acts on CB2 rather than CB1, the receptor responsible for THC’s high, and the 2008 study described it as nonpsychoactive. It is also found in black pepper and cloves.
Does Beta-Caryophyllene Help With Pain or Inflammation?
In mice, oral beta-caryophyllene reduced inflammation and some types of pain through CB2. We found no controlled human trials confirming those effects as part of cannabis.
Which Foods Contain Beta-Caryophyllene?
It is common in spice and food plants, notably black pepper and cloves, and it is also present in hops.
Sources
- Gertsch J et al., “Beta-caryophyllene is a dietary cannabinoid,” PNAS, 2008
- Klauke AL et al., “The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain,” European Neuropsychopharmacology, 2014
- Finlay DB et al., “Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors,” Frontiers in Pharmacology, 2020
- Santiago M et al., “Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ9-THC at Human CB1 and CB2 Receptors,” Cannabis and Cannabinoid Research, 2019
- Elder HJ et al., “A Critical Review of the Interactions Between Δ9-THC and Other Naturally Occurring Phytochemical Constituents of Cannabis sativa,” Current Neuropharmacology, 2026 (online ahead of print)